CRVS — Corvus Pharmaceuticals, Inc. stock price, charts and financials

Latest market price

13.92

+0.55+4.11%

Overview Short InterestFilings

CRVSQT84Corvus Pharmaceuticals, Inc.·NASDAQ

Overview Short InterestFilings

13.92+4.11%

Loading chart...

Signal & projected range

Falling wedge — reversalHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

OCUL+2.26%$8.59 MESO+2.28%$14.80 AUPH+2.47%$14.93 TYRA+1.53%$32.53 URGN+3.45%$39.92 IOVA+0.93%$4.36 STOK+7.14%$31.67 TSHA+7.27%$6.20

Snapshot

Index	-	P/E	-	EPS (ttm)	-	Insider Own	37.56%	Shs Outstand	84.09M	Perf Week	4.58%

Market Cap	1.17B	Forward P/E	-	EPS next Y	-0.87	Insider Trans	0.09%	Shs Float	72.76M	Perf Month	-8.24%

Enterprise Value	1.11B	PEG	-	EPS next Q	-	Inst Own	-	Short Float	24.82%	Perf Quarter	-13.11%

Income	-15.00M	P/S	0.00	EPS this Y	-	Inst Trans	-	Short Ratio	11.44	Perf Half Y	-33.65%

Sales	0.00	P/B	19.19	EPS next Y	-27.77%	ROA	-17.44%	Short Interest	18.06M	Perf YTD	80.78%

Book/sh	0.73	P/C	20.54	EPS next 5Y	-	ROE	-38.92%	52W High	26.95 -48.35%	Perf Year	239.51%

Cash/sh	0.68	P/FCF	-	EPS past 3/5Y	-	ROIC	-19.84%	52W Low	4.05 243.70%	Perf 3Y	507.86%

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-	Gross Margin	0.00%	Volatility	4.50% 5.14%	Perf 5Y	562.86%

Dividend TTM	-	EV/Sales	0.00	EPS Y/Y TTM	49.02%	Oper. Margin	0.00%	ATR (14)	0.74	Perf 10Y	2.43%

Dividend Ex-Date	-	Quick Ratio	19.81	Sales Y/Y TTM	-	Profit Margin	0.00%	RSI (14)	51.44	Recom	2.08

Dividend Gr. 3/5Y	-	Current Ratio	19.81	EPS Q/Q	-15.38%	SMA20	-1.99%	Beta	0.91	Target Price	40.00

Payout	0.00%	Debt/Eq	0.02	Sales Q/Q	-	SMA50	4.66%	Rel Volume	0.54	Prev Close	13.37

Employees	37	LT Debt/Eq	0.02	Earnings	Aug 06	SMA200	6.87%	Avg Volume	1.42M	Price	13.92

IPO Date	Mar 23, 2016	Option/Short	Yes / Yes	EPS/Sales Surpr.	-5.31% -	Net Debt/EBITDA	0.93	Volume	763,784	Change	4.11%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Apr-17-26	Initiated	Goldman Sachs	Buy	$40
Jan-29-26	Reiterated	Mizuho Securities	Outperform	$20 → $30
Jan-22-26	Reiterated	Jefferies	Buy	$13 → $42
Jan-21-26	Reiterated	Oppenheimer	Outperform	$7.00 → $32
Jan-20-26	Reiterated	Mizuho Securities	Outperform	$13 → $20
Jan-20-26	Reiterated	HC Wainwright & Co.	Buy	$27
Oct-29-25	Reiterated	Mizuho Securities	Outperform	$11 → $13
Oct-13-25	Initiated	Barclays	Overweight	$16
May-20-25	Reiterated	Mizuho	Outperform	$12 → $11
Nov-13-24	Reiterated	Jefferies	Buy	$13

Latest News

Jul-30-26

Jul-30-2604:01PM

Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2026 Financial Results on August 6, 2026globenewswire.com

Jul-19-26

Jul-19-2604:01AM

Corvus Pharmaceuticals (NASDAQ:CRVS) Trading Up 5.1% – Should You Buy?defenseworld.net

Jul-01-26

Jul-01-2601:35PM

10 Health Care Stocks With Whale Alerts In Today’s SessionBenzinga

Company

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies. Their leading investigational compound, Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, is currently progressing through Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and head and neck cancers. Another promising candidate, CPI-818, functions as a covalent ITK inhibitor. This therapy is undergoing Phase I/Ib clinical evaluation for patients battling various malignant T-cell lymphomas, aiming to impede the proliferation of specific malignant T-cells. Additionally, Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor, is in Phase II clinical trials for individuals diagnosed with either advanced or refractory renal cell carcinoma. Beyond these clinical-stage assets, Corvus maintains a preclinical portfolio including CPI-182, an antibody designed to block inflammation and myeloid suppression, and CPI-935, an adenosine A2B receptor antagonist intended to prevent fibrosis. The company also benefits from a strategic collaboration with Angel Pharmaceuticals, which aids in advancing its diverse pipeline of targeted experimental drugs. Founded in 2014, Corvus Pharmaceuticals is headquartered in Burlingame, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018	FY 2017 12/31/2017
Total Revenue	0	0	0	0	0	0	0	0	0
Cost of Goods Sold Incl. D&A	0	0	0	0	0	0	0	1	1
Gross Profit	0	0	0	0	0	0	0	-1	-1
Selling, General and Administrative Excl. Other	9	8	7	8	10	12	11	11	10
Research and Development	34	19	17	24	29	32	38	39	46
Other Operating Expense	0	1	-1	1	0	0	0	-1	1
Operating Income	-43	-28	-23	-33	-39	-44	-49	-49	-57
Interest Expense	0	0	0	0	0	1	2	2	0
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	28	-35	-4	-9	-5	38	4	5	1
Net Income Before Taxes	-15	-62	-27	-41	-43	-6	-47	-47	-56
Income Taxes	0	0	0	0	0	0	0	0	0
Consolidated Net Income	-15	-62	-27	-41	-43	-6	-47	-47	-56
Net Income From Continuing Operations	-15	-62	-27	-41	-43	-6	-47	-47	-56
Net Income	-15	-62	-27	-41	-43	-6	-47	-47	-56
EPS (Recurring)	-0.19	-1.02	-0.56	-0.89	-1.03	-0.20	-1.49	-1.71	-2.72
EPS (Basic, Before Extraordinaries)	-0.19	-1.02	-0.56	-0.89	-1.03	-0.20	-1.49	-1.71	-2.72
EPS (Diluted)	-0.53	-1.02	-0.56	-0.89	-1.03	-0.20	-1.49	-1.71	-2.72
EBITDA	-15	-62	-27	-41	-43	-5	-48	-46	-55
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—	—	—
Price To Sales Ratio	—	—	—	—	—	—	—	—	—
Gross Margin	—	—	—	—	—	—	—	—	—
Operating Margin	—	—	—	—	—	—	—	—	—
Net Margin	—	—	—	—	—	—	—	—	—
Shares Outstanding	79	61	48	47	42	29	29	28	20
Market Capitalization	608	326	84	40	101	103	158	103	207
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Moore David Scott	Director	Jun 11 '26	Buy	11.53	21,700	250,236	21,700	Jun 15
MILLER RICHARD A MD	President and CEO	May 18 '26	Buy	12.04	6,932	83,453	1,195,035	May 20
Thompson Peter A.	director, 10 percent owner:	Jan 28 '26	Option Exercise	5.33	210,000	1,119,374	210,000	Jan 30
ORBIMED ADVISORS LLC	director, 10 percent owner:	Jun 27 '25	Option Exercise	3.50	1,397,684	4,891,894	8,341,338	Jul 01
ORBIMED ADVISORS LLC	director, 10 percent owner:	Jun 27 '25	Sale	4.16	1,176,332	4,891,894	7,165,006	Jul 01
Thompson Peter A.	director, 10 percent owner:	Jun 27 '25	Option Exercise	3.50	1,397,684	4,891,894	8,341,338	Jul 01
Thompson Peter A.	director, 10 percent owner:	Jun 27 '25	Sale	4.16	1,176,332	4,891,894	7,165,006	Jul 01
Jones William Benton	See Remarks	Jun 04 '25	Option Exercise	3.50	19,357	67,750	173,130	Jun 06
MILLER RICHARD A MD	President and CEO	May 07 '25	Option Exercise	3.50	559,073	1,956,756	1,136,707	May 09
Thompson Peter A.	director, 10 percent owner:	May 06 '24	Buy	1.72	2,841,769	4,892,038	1,444,085	May 08
ORBIMED ADVISORS LLC	director, 10 percent owner:	May 06 '24	Buy	1.72	2,841,769	4,892,038	1,444,085	May 08
Jones William Benton	See Remarks	May 06 '24	Buy	2.60	39,357	102,374	153,773	May 07
MILLER RICHARD A MD	President and CEO	May 06 '24	Buy	2.60	1,136,707	2,956,756	577,634	May 07
Grais Linda	Director	May 15 '23	Buy	2.45	10,000	24,500	10,000	May 16
Jones William Benton	See Remarks	Dec 20 '22	Buy	0.79	20,000	15,800	133,773	Dec 20

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.